215 filings
6-K
ARGX
Argen X SE
16 Apr 24
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years
6:05am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:14am
6-K
ARGX
Argen X SE
27 Mar 24
Current report (foreign)
6:07am
6-K
ARGX
Argen X SE
26 Mar 24
Regulatory decision in Japan represents first global approval for VYVGART in ITP
6:05am
20-F
2023 FY
ARGX
Argen X SE
Annual report (foreign)
21 Mar 24
6:22am
6-K
iofov
21 Mar 24
Current report (foreign)
6:07am
6-K
11izb hxp
8 Mar 24
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years
6:05am
6-K
2vfiy2qsq fsb
29 Feb 24
Current report (foreign)
4:04pm
6-K
d48kidd6
20 Feb 24
If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn) blocker to treat CIDP
6:06am
SC 13G/A
b0ql681zw
14 Feb 24
ARGENX SE / PRICE T ROWE ASSOCIATES ownership change
10:03am
SC 13G
1ng7 b1hkjk
12 Feb 24
ARGENX SE / Artisan Partners Limited Partnership ownership change
6:08am
SC 13G/A
fzbyu8d q8zrx2
9 Feb 24
ARGENX SE / FMR ownership change
8:35am
SC 13G/A
piejww qn
1 Feb 24
ARGENX SE / BlackRock ownership change
1:04pm
6-K
nnkv y6ig2jky
18 Jan 24
Current report (foreign)
6:10am
6-K
tt2 v8d7pom0jjutm
8 Jan 24
Reported $1.2 billion in preliminary* full-year 2023 global net product sales
6:06am
6-K
3lkgvjk3it8j5hum
20 Dec 23
Current report (foreign)
6:00am
6-K
2bp6x
28 Nov 23
Current report (foreign)
6:01am
6-K
vzgwucgw 7bc0
17 Nov 23
VYVGART® is now approved for both intravenous (IV) and self-administered subcutaneous (SC) use in Europe
6:01am
6-K
vzdvu ylniqyz53n3yl
1 Nov 23
Patients treated with VYVGART experienced consistent improvements on key quality of life measures based on long-term gMG extension data
4:01pm
6-K
i4zk2znuh16e
31 Oct 23
Current report (foreign)
9:14am